The Next Wave of Antibody Therapeutics
World Trade Center Boston
200 Seaport Boulevard
Boston, MA 02210
The Next Wave of Antibody Therapeutics 
 Drug Discovery 

Schedule of Presentations:

Monday, August 3, 2009
07:30:00 Registration and Coffee
08:30:00 Conference Chair Opening Remarks Ulrik B Nielsen
08:35:00 Antibody-Drug Conjugates and Other Conjugation Strategies
08:40:00 Antibody-Drug Conjugates for Cancer Therapy Paul G. Polakis
09:10:00 Preclinical Development of Novel Antibody-Drug Conjugate Technology Based on Potent DNA Damaging Duocarmycins Vincent de Groot
09:40:00 Development of Antibody-Drug Conjugates Targeting Novel Cancer Targets Aya Jakobovits
10:40:00 PSMA ADC, an Antibody-Drug Conjugate as a Potential Prostate Cancer Treatment and Antineovascular Therapy William C. Olson
11:10:00 Novel Antibody-Drug (mAb-SN-38) Conjugates in Solid Tumor Therapy S.V. Govindan
11:40:00 An Antibody-Cytotoxic Conjugate, BIIB015, is a New Targeted Therapy for Cripto Positive Tumors Michele Sanicola-Nadel
12:10:00 Networking Luncheon with Attendee/Speaker Chat Sessions
12:15:00 Immunogenicity of Protein Therapeutics in the Clinic William C. Olson
12:15:00 Antibody-Drug Conjugates Nils Lonberg
12:25:00 Multispecific or Bispecific Antibody Drugs David M. Goldenberg
12:30:00 Considerations When Optimizing Therapeutic Antibodies for Specific Disease Indications Sanjay D. Khare
12:35:00 Pharmacodynamic Biomarkers of Antibodies Frank Calzone
13:30:00 Targeting B-Cell Lymphomas with Inotuzumab Ozogamicin (CMC-544), an Anti-CD22 Immunoconjugate Erik R. Vandendries
14:00:00 MDX-1203: A CD70 Directed Antibody-Drug Conjugate Comprising a Novel Highly Potent Alkylating Agent Nils Lonberg
14:30:00 IMGN901: An Active Maytansinoid Conjugate Targeting CD56 John M. Lambert
15:00:00 Networking Refreshment Break
15:30:00 SGN-35 and SGN-75: Development of Antibody-Drug Conjugates for the Treatment of Cancer Jonathan G. Drachman
16:00:00 CR011-vcMMAE, an Antibody-Drug Conjugate for the Treatment of Melanoma and Breast Cancer Ronit Simantov
16:30:00 Clinical Results of the Phase I and Phase II Studies of Trastuzumab-DM1, A First-in-class HER2 Antibody-Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer Barbara Klencke
17:00:00 Strategic Discussion GroupAntibody-Drug Conjugates and Other Approaches to Enhance Efficacy and Potency Nils Lonberg
17:30:00 Close of Day One
18:00:00 Attendee Networking Dinner
Tuesday, August 4, 2009
08:10:00 Conference Chair Opening Remarks William Dall' Acqua
08:15:00 Approaches to Improve Antibody Efficacy and Potency
08:15:00 Optimizing Targeted Anti-tumor Biologics with Immune Effector Molecules Sanjay D. Khare
08:40:00 Optimizing Antibody Efficacy, Effector Selectivity, and Half-life with Fc Engineering John R. Desjarlais
09:05:00 Biologics for the Treatment of Respiratory Diseases; A Place for Anti-IL-9, Anti-IL5R and Anti-IL-13 Therapies in Bronchial Asthma Alison Humbles
09:30:00 T Cell Engaging BiTE Antibodies: Clinical Proof of Concept and Recent Developments Tobias Raum
09:35:00 Bispecific and Multispecific Drugs
09:55:00 Multi-Specific Adnectins: Realizing the Promise of a Novel Class of Targeted Biologics Sharon Cload
10:20:00 Networking Refreshment Break in Exhibit & Poster Hall
11:00:00 MM-111: A Novel Bispecific Antibody Targeting ErbB3 with Potent Anti-tumor Activity in ErbB2 Over-expressing Malignancies Charlotte McDonagh
11:25:00 DVD-Ig™: A Novel Dual-Targeting Technology Tariq Ghayur
11:50:00 Selection of Stable Single-chain Variable Fragments for Assembly of Anti-PDGFRB/VEGFA Dual-targeting Proteins Robert Mabry
11:55:00 Strategic Discussion Group
12:15:00 Challenges and Risks of Developing Antibodies and Biologics in New Formats Ulrik B Nielsen, John R. Desjarlais, Tobias Raum, Eric Furfine
12:40:00 Networking Luncheon in Exhibit & Poster Hall
12:45:00 Combination Strategies to Enhance Antibody Therapies
12:55:00 Conference Keynote
14:00:00 Antibody Combinations Targeting erbB Receptors in Solid Tumors Mark D. Pegram
14:25:00 Combination and Bispecific Anti-CD20/CD22 Immunotherapy David M. Goldenberg
14:50:00 Combinatorial Strategies for Tumor Inhibition using AMG 479, a Fully Human Monoclonal Antibody that Inhibits the Insulin-like Growth Factor (I) Receptor (IGF-1R) Frank Calzone
15:15:00 Quantitative Prediction of Anti-tumor Antibody Macro and Microdistribution Karl Dane Wittrup
15:40:00 Networking Refreshment Break in Exhibit & Poster Hall
15:45:00 Pharmacodynamic Biomarkers in Antibody Development
16:25:00 Clinical Development of the IGF-IR inhibitor Figitumumab for the Treatment of Cancer Antonio Gualberto
16:50:00 Pharmacodynamic Approach in Early Trials with an Anti-Interferon-a Monoclonal Antibody in Lupus Barbara White
17:15:00 Close of Antibody Therapeutics Main Conference and Proceed to Plenary Keynote
17:20:00 Keynote Introduction Osamu Sato
17:20:00 Plenary Keynote
17:25:00 Global Pharma Innovator: Daiichi Sankyo's Challenge to Build a Competitive Pharmaceutical Company in the Global Market Takashi Shoda
18:00:00 Cocktail Reception in Exhibit & Poster Hall
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.